Home


COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.

 


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $259.6 million in 73 projects around the world.

259.6

$million

Invested

73

innovative

Projects

10

different

Countries

17

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

Vedanta Biosciences’ new VE303 drug will prevent live-threatening C. difficile infections by boosting the body’s microbiome

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

11.30.20

Boston, MA

World Vaccine and Immunotherapy Congress West Coast 2020

12.03.20

Boston, MA

Evidence to Action Webinar: Advancing the Antimicrobial Resistance agenda during a pandemic

12.07.20

 

Milken Institute Future of Health Summit

CARB-X News

  • 11.18.2020  |  CARB-X is funding Clarametyx Biosciences to develop an innovative immune-enabling antibody therapy targeting serious biofilm-associated infections full release

  • 11.10.2020  |  CARB-X is funding Locus Biosciences to develop an innovative CRISPR Cas-3-enhanced bacteriophage targeting antibiotic-resistant Klebsiella pneumoniae infections full release

  • 10.21.2020  |  CARB-X is funding Cellics Therapeutics to develop a novel macrophage nanosponge to prevent and treat sepsis full release

See All News

In The News

  • 11.21.2020  |  Latest CARB-X annual report shows $127.5M, 23 awards doled out for solutions to drug-resistant bacteria full story

  • 11.21.2020  |  If Scientists Don’t Develop New Antibiotics Soon We’ll All Be in a Lot of Trouble full story

  • 11.01.2020  |  Superbugs will kill millions – unless Congress acts full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.